GLP-1.Reviews does not have a medical advisory board, and we are not going to pretend otherwise.
That is a deliberate choice, not a gap. We think it produces better information for the decision you are actually making.
What this site is
We are a verification publisher. We check claims against primary sources and we tell you what those sources say. When we write that the FDA declared the semaglutide shortage resolved on 21 February 2025, that is a fact you can check, and we link you to where to check it. When we write that a provider charges $79 a month, we captured that from their site on a date we publish.
Every article states what it was verified against and when.
What this site is not
We do not practice medicine. We do not tell you which medication to take, what dose to use, whether to start treatment, or whether to stop. Those are decisions for you and a licensed clinician who knows your medical history, and no website — reviewed by a doctor or not — can make them for you.
This is why we do not carry a medical reviewer badge. A badge like that signals that a clinician has vetted health advice. We do not publish health advice, so the badge would be describing something we do not do.
Why we think this is better
Most GLP-1 review sites carry a physician’s name in the byline while ranking providers by affiliate commission. The credential is doing public relations work, not editorial work. It borrows the authority of a profession to lend weight to a commercial ranking.
We would rather show our work. Our scoring formula is published in full. Our sources are linked. Our verification dates are visible. You can check us, which is a stronger form of accountability than a name you have no way to audit.
What we do check
- Regulatory claims against FDA, CMS and the Federal Register directly, never against another publisher’s summary.
- Clinical claims against the drug’s FDA-approved label, the published trial, or a professional society guideline — reported as what that source says, attributed, never restated as our own recommendation.
- Pricing and program claims against the provider’s own live pages, captured with a date.
- Provider conduct against FDA’s public warning letter database, state pharmacy board licensure, and third-party reputation records.
If a clinician ever does review our content
We will publish their full name, credentials, license state and professional profile, and attach the review to the specific articles they read. We will not display a reviewer who does not exist, and we will not describe an editor as a clinician.
Reporting an error
If something here is wrong, tell us at glp1.reviews@gmail.com and we will correct it and date the correction. Pricing and regulatory facts move fast in this category; we would rather be corrected than be stale.
Last updated: September 5, 2026
